Zhang CH, Cheng Y, Zhang S, Fan J, Gao Q. Changing epidemiology of hepatocellular carcinoma in Asia. Liver Int. 2022;42(9):2029–41. https://doi.org/10.1111/liv.15251. PMID: 35319165.

Article  PubMed  Google Scholar 

Maki H, Hasegawa K. Advances in the surgical treatment of liver cancer. Biosci Trends. 2022;16(3):178–88. https://doi.org/10.5582/bst.2022.01245. PMID: 35732434.

Article  CAS  PubMed  Google Scholar 

Torimura T, Iwamoto H. Treatment and the prognosis of hepatocellular carcinoma in Asia. Liver Int. 2022;42(9):2042–54. https://doi.org/10.1111/liv.15130. PMID: 34894051.

Article  PubMed  Google Scholar 

Liu M, Xu M, Tang T. Association between chemotherapy and prognostic factors of survival in hepatocellular carcinoma: a SEER population-based cohort study. Sci Rep. 2021;11(1):23754. https://doi.org/10.1038/s41598-021-02698-x. PMID: 34887446.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Takei S, Kawazoe A, Shitara K. The new era of immunotherapy in gastric cancer. Cancers (Basel). 2022;14(4):1054. https://doi.org/10.3390/cancers14041054. PMID: 35205802.

Article  CAS  PubMed  Google Scholar 

Chen Y, Hu H, Yuan X, Fan X, Zhang C. Advances in immune checkpoint inhibitors for advanced hepatocellular carcinoma. Front Immunol. 2022;13:896752. https://doi.org/10.3389/fimmu.2022.896752. PMID: 35757756.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vafaei S, Zekiy AO, Khanamir RA, Zaman BA, Ghayourvahdat A, Azimizonuzi H, Zamani M. Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier. Cancer Cell Int. 2022;22(1):2. https://doi.org/10.1186/s12935-021-02407-8. PMID: 34980128.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xing R, Gao J, Cui Q, Wang Q. Strategies to improve the antitumor effect of immunotherapy for hepatocellular carcinoma. Front Immunol. 2021;12:783236. https://doi.org/10.3389/fimmu.2021.783236. PMID: 34899747.

Article  CAS  PubMed  PubMed Central  Google Scholar 

El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH, Meyer T, Kang YK, Yeo W, Chopra A, Anderson J, Dela Cruz C, Lang L, Neely J, Tang H, Dastani HB, Melero I. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–502. https://doi.org/10.1016/S0140-6736(17)31046-2. PMID: 28434648.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Finn R, Ryoo B, Merle P, Kudo M, Bouattour M, Lim H, Breder V, Edeline J, Chao Y, Ogasawara S, Yau T, Garrido M, Chan S, Knox J, Daniele B, Ebbinghaus S, Chen E, Siegel A, Zhu A, Cheng A. Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC). J Clin Oncol. 2019;37(15):4004–4. https://doi.org/10.1200/jco.2019.37.15_suppl.4004.

Article  Google Scholar 

Bang YJ, Golan T, Dahan L, Fu S, Moreno V, Park K, Geva R, De Braud F, Wainberg ZA, Reck M, Goff L, Laing N, Mi G, Oliveira JM, Wasserstrom H, Lin CC. Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: an open-label, phase Ia/b study (JVDJ). Eur J Cancer. 2020;137:272–84. https://doi.org/10.1016/j.ejca.2020.06.007. PMID: 32827847.

Article  CAS  PubMed  Google Scholar 

Lin ZF, Qin LX, Chen JH. Biomarkers for response to immunotherapy in hepatobiliary malignancies. Hepatob Pancreat Dis. 2022;21(5):413–9. https://doi.org/10.1016/j.hbpd.2022.08.002. PMID: 35973935.

Article  Google Scholar 

Ao H, Xin Z, Jian Z. Liquid biopsy to identify biomarkers for immunotherapy in hepatocellular carcinoma. Biomark Res. 2021;9(1):91. https://doi.org/10.1186/s40364-021-00348-y. PMID: 34930486.

Article  PubMed  PubMed Central  Google Scholar 

De Marchi P, Leal LF, Duval da Silva V, da Silva ECA, Cordeiro de Lima VC, Reis RM. PD-L1 expression by Tumor Proportion Score (TPS) and Combined Positive Score (CPS) are similar in non-small cell lung cancer (NSCLC). J Clin Pathol. 2021;74(11):735–40. https://doi.org/10.1136/jclinpath-2020-206832. PMID: 33589532.

Article  CAS  PubMed  Google Scholar 

Formica V, Morelli C, Patrikidou A, Shiu KK, Nardecchia A, Lucchetti J, Roselli M, Arkenau HT. A systematic review and meta-analysis of PD-1/PD-L1 inhibitors in specific patient subgroups with advanced gastro-oesophageal junction and gastric adenocarcinoma. Crit Rev Oncol Hemat. 2021;157:103173. https://doi.org/10.1016/j.critrevonc.2020.103173. PMID: 33278677.

Article  CAS  Google Scholar 

Kim H, Hong JY, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kim KM, Kim ST. Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors. Ther Adv Med Oncol. 2021;13:1758835921992992. https://doi.org/10.1177/1758835921992992. PMID: 33717226.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun H, Chen L, Huang R, Pan H, Zuo Y, Zhao R, Xue Y, Song H. Prognostic nutritional index for predicting the clinical outcomes of patients with gastric cancer who received immune checkpoint inhibitors. Front Nutr. 2022;9:1038118. https://doi.org/10.3389/fnut.2022.1038118. PMID: 36438745.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sonehara K, Tateishi K, Araki T, Komatsu M, Yamamoto H, Hanaoka M. Prognostic value of the geriatric nutritional risk index among patients with previously treated advanced non-small cell lung cancer who subsequently underwent immunotherapy. Thorac Cancer. 2021;12(9):1366–72. https://doi.org/10.1111/1759-7714.13909. PMID: 33710780.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tian BW, Yang YF, Yang CC, Yan LJ, Ding ZN, Liu H, Xue JS, Dong ZR, Chen ZQ, Hong JG, Wang DX, Han CL, Mao XC, Li T. Systemic immune-inflammation index predicts prognosis of cancer immunotherapy: systemic review and meta-analysis. Immunotherapy. 2022;14(18):1481–96. https://doi.org/10.2217/imt-2022-0133. PMID: 36537255.

Article  CAS  PubMed  Google Scholar 

Wu M, Liu J, Wu S, Liu J, Wu H, Yu J, Meng X. Systemic immune activation and responses of irradiation to different metastatic sites combined with immunotherapy in advanced non-small cell lung cancer. Front Immunol. 2021;12:803247. https://doi.org/10.3389/fimmu.2021.803247. PMID: 34970277.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Muhammed A, Fulgenzi CAM, Dharmapuri S, Pinter M, Balcar L, Scheiner B, Marron TU, Jun T, Saeed A, Hildebrand H, Muzaffar M, Navaid M, Naqash AR, Gampa A, Ozbek U, Lin JY, Perone Y, Vincenzi B, Silletta M, Pillai A, Wang Y, Khan U, Huang YH, Bettinger D, Abugabal YI, Kaseb A, Pressiani T, Personeni N, Rimassa L, Nishida N, Di Tommaso L, Kudo M, Vogel A, Mauri FA, Cortellini A, Sharma R, D’Alessio A, Ang C, Pinato DJ. The systemic inflammatory response identifies patients with adverse clinical outcome from immunotherapy in hepatocellular carcinoma. Cancers (Basel). 2021;14(1):186. https://doi.org/10.3390/cancers14010186. PMID: 35008350.

Article  CAS  PubMed  Google Scholar 

Zhao M, Duan X, Mi L, Shi J, Li N, Yin X, Han X, Wang J, Han G, Hou J, Yin F. Prognosis of hepatocellular carcinoma and its association with immune cells using systemic inflammatory response index. Future Oncol. 2022;18(18):2269–88. https://doi.org/10.2217/fon-2021-1087. PMID: 35440159.

Article  CAS  PubMed  Google Scholar 

Scheiner B, Pomej K, Kirstein MM, Hucke F, Finkelmeier F, Waidmann O, Himmelsbach V, Schulze K, von Felden J, Fründt TW, Stadler M, Heinzl H, Shmanko K, Spahn S, Radu P, Siebenhüner AR, Mertens JC, Rahbari NN, Kütting F, Waldschmidt DT, Ebert MP, Teufel A, De Dosso S, Pinato DJ, Pressiani T, Meischl T, Balcar L, Müller C, Mandorfer M, Reiberger T, Trauner M, Personeni N, Rimassa L, Bitzer M, Trojan J, Weinmann A, Wege H, Dufour JF, Peck-Radosavljevic M, Vogel A, Pinter M. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score. J Hepatol. 2022;76(2):353–63. https://doi.org/10.1016/j.jhep.2021.09.035. PMID: 34648895.

Article  CAS  PubMed  Google Scholar 

Guan R, Mei J, Lin W, Deng M, Li S, Guo R. Is the CRAFITY score a superior predictor of prognosis and adverse events in hepatocellular carcinoma patients treated with locoregional-immunotherapy? Hepatol Int. 2023;17(5):1279–88. https://doi.org/10.1007/s12072-023-10535-8. PMID: 37129721.

Article  PubMed  Google Scholar 

Shoji F, Takeoka H, Kozuma Y, Toyokawa G, Yamazaki K, Ichiki M, Takeo S. Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors. Lung Cancer. 2019;136:45–51. https://doi.org/10.1016/j.lungcan.2019.08.006. PMID: 31437663.

Article  PubMed  Google Scholar 

Chen Y, Zhang C, Peng Z, Qi C, Gong J, Zhang X, Li J, Shen L. Association of lymphocyte-to-monocyte ratio with survival in advanced gastric cancer patients treated with immune checkpoint inhibitor. Front Oncol. 2021;11:589022. https://doi.org/10.3389/fonc.2021.589022. PMID: 34141607.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mountzios G, Samantas E, Senghas K, Zervas E, Krisam J, Samitas K, Bozorgmehr F, Kuon J, Agelaki S, Baka S, Athanasiadis I, Gaissmaier L, Elshiaty M, Daniello L, Christopoulou A, Pentheroudakis G, Lianos E, Linardou H, Kriegsmann K, Kosmidis P, El Shafie R, Kriegsmann M, Psyrri A, Andreadis C, Fountzilas E, Heussel CP, Herth FJ, Winter H, Emmanouilides C, Oikonomopoulos G, Meister M, Muley T, Bischoff H, Saridaki M, Christopoulos P. Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer. ESMO Open. 2021;6(5):100254. https://doi.org/10.1016/j.esmoop.2021.100254. PMID: 34481329.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gou M, Qu T, Wang Z, Yan H, Si Y, Zhang Y, Dai G. Neutrophil-to-lymphocyte ratio (NLR) predicts PD-1 inhibitor survival in patients with metastatic gastric cancer. J Immunol Res. 2021;2021:2549295. https://doi.org/10.1155/2021/2549295. PMID: 34993252.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang Y, Lu L, He Z, Xu Z, Xiang Z, Nie RC, Lin W, Chen W, Zhou J, Yin Y, Xie J, Zhang Y, Zheng X, Zhu T, Cai X, Li P, Chao X, Cai MY. C-reactive protein levels predict responses to PD-1 inhibitors in hepatocellular carcinoma patients. Front Immunol. 2022;13:808101.